Waystar (WAY) Q1 2026: AI Drives 40% of New Bookings, Expanding Platform TAM
Waystar’s AI-powered platform is reshaping the healthcare revenue cycle, now fueling 40% of new bookings and broadening the company’s addressable market far beyond traditional software. While digital transformation in patient payments created short-term revenue offsets, core provider solutions and new AI SKUs are driving margin expansion and deepening customer integration. Management’s conviction in platform adoption and cross-sell momentum signals durable growth, with visibility into 2027 and beyond.
Summary
- AI Embedded Workflows Accelerate: Nearly half of new bookings are AI-driven, signaling a shift toward automation and platform stickiness.
- Margin Expansion from Mix Shift: Provider solutions outpace patient payments, supporting higher profitability and resilience.
- Platform Adoption Deepens: Elevated pipeline and backlog reflect multi-year customer commitments and growing acute market traction.
Performance Analysis
Waystar’s Q1 results underscore the company’s evolution from a healthcare RCM (revenue cycle management) software provider to a platform automating core industry workflows through AI. Total revenue rose sharply, supported by both organic growth and contributions from the Iodine acquisition, with subscription revenue now making up more than half the total. Provider solutions, representing approximately 75% of revenue, grew at double the rate of lower-margin patient payment solutions, driving margin improvement and adjusted EBITDA expansion.
Volume-based revenue growth moderated amid accelerated migration from print to digital patient statements and softer patient utilization trends, a dynamic management framed as a positive long-term shift toward digital engagement rather than a competitive threat. Net revenue retention remained above historical averages, and client wins included 42 new accounts generating over $100,000 in annual revenue, reflecting robust demand across both new and existing customers.
- AI-Driven Bookings Surge: AI-powered solutions accounted for 40% of new bookings, with early adoption of new SKUs like the recoupment solution showing rapid ROI for providers.
- Margin Leverage from Mix: Higher-margin provider solutions offset lower-growth patient payments, supporting a 43% adjusted EBITDA margin.
- Backlog and Pipeline at Record Levels: Implementation backlog and qualified sales pipeline are at all-time highs, providing strong revenue visibility into future periods.
Waystar’s capital position remains healthy with strong cash flow conversion and ongoing deleveraging, further supported by recent credit rating upgrades. Management reaffirmed full-year guidance, balancing near-term volume offsets with confidence in late-2026 growth from large, multi-solution platform deals.
Executive Commentary
"AI-powered capabilities drove roughly 40% of new bookings in Q1, and our clients leaned into the platform for prevention, automation, and visibility, rather than downstream rework. That shift reflects the value of embedded intelligence across the revenue cycle."
Matt Hawkins, Chief Executive Officer
"Provider solutions, which have higher margins and comprise approximately 75% of revenue, organically grew year-over-year at double the rate of lower margin patient payment solutions. That conversion is neutral [to] cash flow. So we see positivity long-term in the business there because it's going to allow us to see margin accretion in the business overall."
Steve Oreskevich, Chief Financial Officer
Strategic Positioning
1. AI as a Revenue and TAM Expander
Waystar’s integration of agentic AI—AI that can autonomously execute multi-step tasks—into core revenue cycle workflows is unlocking a much larger market. By automating manual labor in claims, denials, and recoupment, the company is shifting its TAM (total addressable market) from a $20 billion software niche to a $100 billion services pool. Management highlighted the launch of new AI SKUs, such as pre-bill anomaly detection and recoupment solutions, as proof points for this expansion.
2. Platform Stickiness and Cross-Sell Momentum
Waystar’s platform is increasingly viewed as mission-critical infrastructure by providers. Integrated workflows, proprietary data rails, and deep EHR (electronic health record) integrations create high switching costs and foster multi-year customer commitments. Cross-sell and upsell activity is robust, especially as larger provider organizations consolidate vendors and standardize on unified platforms.
3. Margin Expansion via Revenue Mix Shift
Provider solutions are not only growing faster but also carry structurally higher margins than patient payment solutions. The accelerated shift to digital in patient payments, while neutral to cash flow, supports long-term margin expansion by reducing third-party costs and enhancing operational leverage.
4. Acute Segment Gains and Iodine Integration
Waystar’s foothold in the acute (hospital) segment is growing, now representing about 40% of revenue and including relationships with 16 of the top 20 U.S. health systems. The integration of Iodine, which brings clinical data and AI talent, is ahead of schedule and expanding the company’s mid-cycle capabilities—an area identified as a major unmet need by recent third-party research.
Key Considerations
This quarter’s results highlight a company in the midst of a multi-year transformation, leveraging AI to expand its value proposition and customer base while maintaining discipline in execution and capital allocation.
Key Considerations:
- AI Monetization Pathways: New SKUs and embedded AI are priced to value, with early adopter programs and robust training to accelerate adoption and realization of ROI.
- Sales Cycle Stability Amid Larger Deals: Despite larger, multi-solution contracts, sales cycles remain stable, with win rates improving and implementation backlogs building.
- Digital Transformation in Patient Payments: The shift from print to digital is a structural positive for both providers and Waystar, supporting engagement and margin even as it moderates top-line growth in the near term.
- Resilience to Macro and Payer-Provider Tensions: Waystar’s platform is prioritized by providers even in challenging hospital financing environments, and the company is positioned as a constructive intermediary as payers and providers both deploy AI.
Risks
Waystar’s growth trajectory is not immune to macro headwinds, including patient utilization volatility, payer pushback, and hospital financial pressures. The company’s expansion into new AI-powered services introduces execution and adoption risk, and the long ramp times for large deals could delay revenue realization. Continued digital migration in patient payments, while margin-accretive, may suppress revenue growth rates in the near term.
Forward Outlook
For Q2, Waystar guided to:
- Sequential revenue growth of flat to 1% (reflecting patient payment offsets and digital migration)
- Adjusted EBITDA margin maintained at strong levels, with margin shape expected to be stable through the year
For full-year 2026, management reaffirmed guidance:
- Revenue range of $1.274 billion to $1.294 billion (17% YoY growth at midpoint)
- Adjusted EBITDA range of $530 million to $540 million
Management emphasized continued investment in innovation, client experience, and cybersecurity, with a focus on driving cross-sell, platform adoption, and operational discipline. The record pipeline and backlog are expected to support growth into late 2026 and 2027, while near-term revenue growth will be tempered by the digital transition in patient payments.
Takeaways
- AI as Growth Catalyst: AI-embedded workflows and new SKUs are driving bookings, expanding TAM, and supporting higher margin structure, with early results validating the monetization strategy.
- Platform Adoption and Stickiness: Multi-solution deals, record pipeline, and deepening acute market penetration reinforce Waystar’s position as a mission-critical RCM platform.
- Watch for Digital Shift Impact: Investors should monitor the impact of digital migration on patient payments and the timing of large deal revenue recognition as indicators of execution and future growth durability.
Conclusion
Waystar’s Q1 2026 results highlight a business successfully navigating digital and AI-driven transformation, with platform adoption and margin expansion outpacing short-term revenue offsets. The company’s strategic focus on AI, platform integration, and cross-sell momentum positions it for sustained growth, though investors should remain attentive to execution risks and the impact of industry shifts on near-term results.
Industry Read-Through
Waystar’s performance and commentary underscore a pivotal industry trend: the migration from point solutions to integrated, AI-powered platforms in healthcare revenue cycle management. As providers seek to automate manual processes and manage payer complexity, demand is shifting toward vendors that can deliver end-to-end solutions with embedded intelligence and data integration. The accelerating digital transformation in patient engagement and the race to deploy agentic AI across workflows signal that scale, data, and workflow integration will define future winners. Competitors relying on legacy, non-integrated offerings face increasing risk of disintermediation, while those that can bridge clinical and financial data stand to capture expanding value pools as the service-to-software transition accelerates.